Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Victoria Speed; Lara N. Roberts; Roopen Arya; Jignesh P. Patel

doi:10.1111/jth.15196

King's College London

King's main site

Research portal

Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Research output: Contribution to journal › Letter › peer-review

Victoria Speed, Lara N. Roberts, Roopen Arya, Jignesh P. Patel

Original language	English
Pages (from-to)	872-873
Number of pages	2
Journal	Journal of Thrombosis and Haemostasis
Volume	19
Issue number	3
Early online date	2 Mar 2021
DOIs	https://doi.org/10.1111/jth.15196
E-pub ahead of print	2 Mar 2021
Published	Mar 2021
Additional links	Link to publication in Scopus

Bibliographical note

Funding Information: V. Speed declares no competing interests. Dr. Roberts has received speaker fees and travel grant from Bayer, and investigator‐initiated research grant and travel grant from Sanofi. Dr. Arya reports grants from Bayer; personal fees from Bayer, Pfizer, Medtronic, and Sanofi; and nonfinancial support from Bayer, Pfizer, and Sanofi. Dr. Patel has received an investigator‐initiated research grant from Bayer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

King's Authors

View graph of relations

King's College London - Homepage

Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment

Bibliographical note

King's Authors

By the same authors

With some of the same researchers

From the same journal